Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
High Confidence RCTPrimary source: [Open]
Outcomes summary
Randomized trial in type 2 diabetes comparing tirzepatide doses to semaglutide 1 mg; tirzepatide achieved greater HbA1c reduction and greater weight loss than semaglutide, with gastrointestinal adverse events common.
Limitations
Applies to the studied population and comparator dose; adverse events and tolerability depend on titration and dose.
Notes
Primary source: PMID 34170647 (see PubMed link on this page).